clinical trial · NCT07349693
Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
Everfront Biotech Co., Ltd.·phase3·not yet recruiting·n = 175
Recurrent Glioblastoma, IDH-WildtypeCerebraca waferTemozolomide (for relapsed malignant glioma)
brief summary
This study is designed as a multi-center, randomized, open-label trial to evaluate the efficacy of Cerebraca Wafer in patients with recurrent glioblastoma. Cerebraca Wafer is intended for use in recurrent glioblastoma as an adjunct to surgery (followed by standard-of-care temozolomide), demonstrating potential to improve outcomes in this serious and life-threatening condition
started
Nov 1, 2026
primary completion
Dec 1, 2028
completion
Dec 1, 2030
last updated
Jan 20, 2026
official title
A Randomized Trial to Assess the Efficacy and Safety of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol